HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Toxicity Testing For Topical Drugs, Sunscreens Included, On Tap In US FDA Workshop

This article was originally published in The Rose Sheet

Executive Summary

While FDA does not identify specific product types on the agenda for its public workshop on approaches in skin toxicity testing for topical drug products, advocacy and trade groups anticipate sunscreen ingredient testing could be among the discussion topics. Product expansions have been stifled by regulatory concerns, drawing particular attention from the public health community.

Advertisement

Related Content

FDA Shopping For 3D Tissue Bioprinter, Cosmetic Contamination Testing Services
US FDA's Sunscreen Progress Gets Dim Review From Congressional Appropriators
Appropriators Agree On Boosting FDA's Supplement Sector Work, Not On Funding
Exclusivity Period Allowed By OTC Monograph Reform Likely Up To Conference Committee
Feminine Cleanser Marketing Never Without Challenges; Now The Category Has FDA’s Attention
Pediatric Studies Of Systemic Atopic Dermatitis Drugs Should Start Earlier, US FDA Says
Sunscreen Industry Asks FDA For Flexibility Despite Guidances' Rigidity
Sunscreen Group Remains Cloudy About FDA's Ingredient Evaluations
Nestle's Prospects To Lead OTC Acne Market Gel With Differin Approval
Galderma Pioneers NDA Path Into OTC Acne Treatment Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

RS121781

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel